CAS: 115520-21-3; Fmoc-Cys(Trt)-Opfp

相似化合物

86060-94-8 200395-72-8 86060-95-9

上下游产品

CAS号14533-84-7 三氟乙酸五氟苯酯 | CAS号103213-32-7 Fm°C-S-三苯甲基-L-半胱氨酸 | CAS号771-61-9 五氟苯酚

五氟苯酚置于吡啶体系中,用 N,N-二甲基甲酰胺 用作溶剂,化学反应 0.75H,反应生成N-芴甲氧羰基-S-三苯甲基-L-半胱氨酸五氟苯酯
参考文献:Preparation Of Pentafluorophenyl Esters Of Fmoc Protected Amino Acids With Pentafluorophenyl Trifluoroacetate
标题:Preparation Of Pentafluorophenyl Esters Of Fmoc Protected Amino Acids With Pentafluorophenyl Trifluoroacetate
摘要:
Doi:10.1016/s0040-4039(00)97976-0

专利信息

专利号:US-9695214-B2
优先权日:2013-03-15
标 题 :Solid phase peptide synthesis processes and associated systems
发明人：SIMON MARK DAVID; PENTELUTE BRADLEY L; ADAMO ANDREA; HEIDER PATRICK LOUIS; JENSEN KLAVS F
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:Systems and processes for performing solid phase peptide synthesis are generally described. Solid phase peptide synthesis is a known process in which amino acid residues are added to peptides that have been immobilized on a solid support. In certain embodiments, the inventive systems and methods can be used to perform solid phase peptide synthesis quickly while maintaining high yields. Certain embodiments relate to processes and systems that may be used to heat, transport, and/or mix reagents in ways that reduce the amount of time required to perform solid phase peptide synthesis.

专利号:WO-9837097-A1
优先权日:1997-02-21
标 题:Msh-receptor subtype selective cyclic peptides
发明人：WIKBERG JARL; MUCENIECE RUTA; MUTULIS FELIKSS; PRUSIS PETERIS; SCHIOETH HELGI-BIRGIR
权利人:WAPHARM AB; WIKBERG JARL; MUCENIECE RUTA; MUTULIS FELIKSS; PRUSIS PETERIS; SCHIOETH HELGI BIRGIR
摘要:Cyclic MC-receptor activating and/or blocking peptides of general formula (I) in which LRG is a large aminoacid and L is 26-29 membered linker connecting LRG and Trp are useful for treating conditions related to eating, body weight, motivation, learning, memory, behaviour, inflammation, body temperature, pain perception, blood pressure, heart rate, vascular tone, natriuresis, brain blood flow, nerve growth, placental development, aldosteron synthesis and release, thyroxin release, spermatogenesis, ovarian weight, prolacting and FSH secretion, uterine bleeding in women, sebum and pheromone secretion, blood glucose levels, intrauterine foetal growth, as well as other events related to parturition, and to afford neuroprotection. The novel peptides can also be labeled and be incorporated into pharmaceutical compositions.